Primary Immunodeficiency Disease Clinical Trial
Official title:
Clinical Characteristics and Prognosis of Primary Immunodeficiency Disease (PID) in Chinese Children
This study is a prospective cohort study of children diagnosed with primary immunodeficiency disease (PID). The aim is to investigate the clinical characteristics and prognosis of PID in Chinese children.
Primary immunodeficiency disease (PID) is a group of rare and fatal disease. However, the
research about clinical characteristics, treatment, management and prognosis of Chinese
children with PID is still not perfect and there is no basic and large database. Therefore,
this study is conducted, in order to set up a complete database and long term follow up of
Chinese children with PID, and establish foundations for basic research and precise medicine.
This study is divided into two parts. In part one, pediatric patients with PID in the past 10
years will be collected retrospectively by review medical records from these centers, and
investigate the clinical features and prognosis. In part two, all new cases with suspected
PID will be collected. Clinical symptoms, physical examination, blood tests, and humoral and
cellular immune functions will be detected. Gene tests would be done when necessary to
confirm the diagnosis. Then follow up at 6-moth, 1-year, 2-year, 3-year, 4-year and 5-year
respectively. The trial will be completed in 60 months.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03677557 -
Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment
|
Phase 4 | |
| Completed |
NCT02810444 -
Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID
|
Phase 3 | |
| Enrolling by invitation |
NCT01150240 -
Clinical and Laboratory Online Patient- and Research Database for Primary Immunodeficiencies in Switzerland
|
N/A | |
| Recruiting |
NCT04944979 -
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)
|
Phase 3 | |
| Completed |
NCT02627300 -
Study of Octanorm Subcutaneous IG in Patients With Primary Immunodeficiency Diseases Who Have Completed the SCGAM-01 Trial
|
Phase 3 | |
| Completed |
NCT03961009 -
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients
|
Phase 3 | |
| Completed |
NCT04842643 -
An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease
|
Phase 3 | |
| Not yet recruiting |
NCT06089122 -
Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG
|
Phase 3 | |
| Not yet recruiting |
NCT06150833 -
Efficacy and Safety and Pharmacokinetics of Boya IVIG
|
Phase 3 |